Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | FAAH | O00519 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663293 | 0.90 | FAAH (0.58) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL5085765 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL844472 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL14040614 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL2320404 | 0.87 | FAAH (0.59) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL4265545 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL4097623 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL5181827 | 0.87 | KMT2A (0.53) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL5085949 | 0.86 | FAAH (0.50) | SMN1; SMN2FAAHNPC1RAB9AHPGD | |
| SCHEMBL2367175 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2FAAHNPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | SMN1; SMN2 3356/4885FAAH 1826/4885NPC1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.